Search

Displaying results 2671 - 2680 of 7479 in total
  1. Drug

    Rufinamide

    go.drugbank.com/drugs/DB06201
    Approved

    Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy.

  2. Drug

    Flufenamic acid

    go.drugbank.com/drugs/DB02266
    Approved

    An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically.

  3. Drug

    Aluminum chlorohydrex propylene glycol

    go.drugbank.com/drugs/DB11208
    Approved

    It is an antiperspirant active ingredient found in antiperspirant drug products for over-the-counter human use.

  4. Drug

    Ethchlorvynol

    go.drugbank.com/drugs/DB00189
    ApprovedIllicitWithdrawn

    It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists.

  5. Drug

    Tisagenlecleucel

    go.drugbank.com/drugs/DB13881
    ApprovedInvestigational

    Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric

  6. Drug

    Influenza B virus B/Austria/1359417/2021 recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB16923
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

  7. Drug

    Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB18750
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

    Synonyms: Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated)
  8. Drug

    Influenza A virus A/District of Columbia/27/2023 (H3N2) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB22669
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

  9. Drug

    Influenza A virus A/Victoria/800/2024 CVR-289 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB22671
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

  10. Drug

    Influenza A virus A/Perth/722/2024 (H3N2) live (attenuated) antigen

    go.drugbank.com/drugs/DB31654
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.